This market research report presents an in depth analysis of hERG Screening. The research study emphasizes on both the technology and product segments of hERG Screening in biotechnology and pharmaceutical application areas. The research report provides essential information including market data, segmentation, market size, key trends, M&A, product developments, industry forecasts, corporate intelligence, and other relevant information. The research report lists 128 companies that are engaged in hERG Screening services and/or production of hERG Screening tools/instruments. Projections and estimates are graphically represented by region. A global perspective is presented along with regional analysis covering the regions of North America, Europe, Asia-Pacific and Rest of World. The market is analyzed in US Dollars and includes 32 exclusive exhibits of this market research report.

Free Sample Research Report

Download Table of contents

Human Ether-a-go-go Related Gene (hERG gene) (KCNH2) is an encoder of the potassium ion channel that repolarizes IKr current in the heart. It consists of 6 transmembrane domains which are serially numbered from S1-S6. The abnormalities resulting in this channel can either lead to Long QT syndrome (LQT2) or Short QTsyndrome causing loss of function mutations and gain of function mutations respectively. Both of these are considered as potentially fatal cardiac arrhythmia caused due to repolarisation disturbances of the cardiac action potential.

Global hERG Screening market is projected to grow at 26.48%, compounded annually from 2005 through 2012. The growth is driven especially by screening of drugs for hERG in early stages of drug discovery and development. hERG which encodes the potassium ion channel is considered responsible for repolarizing IKr current in the cardiac action potential.

hERG screening has taken center stage given its increasing significance in screening cardiac side effects of drugs. Also added is the fact that blocking of hERG potassium channel is connected with LQTS prolongation and Torsades de Pointes. Many drug like molecules have an affinity for the hERG channel, and this is leading to a robust growth in pharmaceutical hERG screening of lead compounds. Pharma companies are rising to the challenge to develop leads and products useful for pharma and biotech applications. hERG screening is either developed inhouse or outsourced. Ionchannel protein complexes are promising therapeutic agents. Drugs modulation ion channel activity are in great demand for application in medication, CNS disorders, cardiovascular disorders, metabolic disorders, and now in oncology too.

Abcam PLC (UK)
Abnova Corp. (Taiwan)
ABR-Affinity BioReagents, Inc. (USA)
Astrazeneca PLC (UK)
Aureus Pharma (France)
Aurora Biomed, Inc. (Canada)
AutoMate Scientific, Inc. (USA)
AVIVA Biosciences Corporation (USA)
bSys GmbH (Switzerland)
Caliper Life Sciences, Inc. (USA)
Cambridge BioScience Ltd (UK)
Cellular Dynamics International (USA)
Cerep SA (France)
ChanTest Corporation (USA)
Charles River Laboratories, Inc. (USA)
ChemAxon Kft. (Hungary)
CorDynamics (USA)
Covance, Inc. (USA)
CreaCell (France)
Cyprotex plc (UK)
Cytocentrics AG (Germany)
Flyion GmbH (Germany)
Invitrogen, Inc. (USA)
Lifespan Biosciences, Inc. (USA)
MDS, Inc (Canada)
Millipore Corporation (USA)
Molecular Devices Corporation (USA)
Nanion Technologies GmbH (Germany)
Neurion Pharmaceuticals, Inc. (USA)
Neurosolutions Ltd. (UK)
Novascreen Biosciences Corporation (USA)
Novus Biologicals, Inc. (USA)
RCC Ltd. (Switzerland)
RDDT (Australia)
Santa Cruz Biotechnology, Inc. (USA)
Schrodinger, LLC (USA)
Sigma-Aldrich Corporation (USA)
Sophion Bioscience A/S (Denmark)
Strand Life Sciences (India)
Synergia Life sciences (India)
Tetra Q (Australia)
Tocris Bioscience (USA)
Wisconsin Alumni Research Foundation (WARF) (USA)
WuXi PharmaTech Co.Ltd (China)

For those who are intrested to buy the report by chapter:

CHAPTER	TITLE	SHORT DESCRIPTION	PRICE (US$)
I	Scope and Methodology	This chapter provides information regarding the research methodology, limitations of the study, market measuring units and exchange rates used. * Will be delivered free with purchase of any of the other chapters mentioned below.	FREE*
II	Report Synopsis	Synopsis of the report summarizes the global hERG Screening market. The chapter provides market values in US$ for hERG Screening in several geographic regions including the North America, Europe, Asia-Pacific and rest of world.	$1000
III	Product / Technology Research	This chapter gives an insight into hERG Screening market including definitions, segmentation and applications. The chapter also provides market values in US$ (for the period 2005 through 2012) for hERG Screening. The chapter also includes product trends and potential opportunities. Importance of hERG Screening in the drug discovery process, technology analysis and technology trends are discussed.	$800
IV	Market Dynamics	Market Dynamics chapter provides information on global markets for hERG Screening. The chapter includes global market analysis (in US$) by geographic region; analysis of each region; a brief business profile of major global companies; and a report of corporate activities such as mergers and acquisitions, partnerships, new product developments/launches etc. The chapter also includes market trends and an industry outlook.	$1350
V	Corporate Directory	This chapter provides a global region-wise list of 121 companies, CROs and academic institutions that are engaged in hERG Screening products and/or services.	$300